Carregant...
Rofecoxib and Clinically Significant Upper and Lower GI Events Revisited based on documents from recent litigation.
BACKGROUND: Based on published data, it is widely believed and cited that rofecoxib use is associated with approximately a 50% reduction in significant gastrointestinal complications such as bleeding. METHODS: Data made available as part of litigation, including the VIGOR trial and an Azlheimers’ st...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3203315/ https://ncbi.nlm.nih.gov/pubmed/21986300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MAJ.0b013e3182113658 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|